{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:48:08Z","timestamp":1790380088285,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PATH, United States","award":["KFW.0888-38-01710369-SUB"],"award-info":[{"award-number":["KFW.0888-38-01710369-SUB"]}]},{"name":"PATH, United States","award":["KFW.0888-38-01710369-SUB"],"award-info":[{"award-number":["KFW.0888-38-01710369-SUB"]}]},{"name":"PATH, United States","award":["KFW.0888-38-01710369-SUB"],"award-info":[{"award-number":["KFW.0888-38-01710369-SUB"]}]},{"name":"PATH, United States","award":["KFW.0888-38-01710369-SUB"],"award-info":[{"award-number":["KFW.0888-38-01710369-SUB"]}]},{"name":"PATH, United States","award":["KFW.0888-38-01710369-SUB"],"award-info":[{"award-number":["KFW.0888-38-01710369-SUB"]}]},{"name":"PATH, United States","award":["KFW.0888-38-01710369-SUB"],"award-info":[{"award-number":["KFW.0888-38-01710369-SUB"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Africa has some of the highest cervical cancer incidence and mortality rates globally. Burkina Faso launched a human papillomavirus (HPV) vaccination programme for 9-year-old girls in 2022 with support from Gavi, the Vaccine Alliance (Gavi). An economic evaluation of HPV vaccination is required to help sustain investment and inform decisions about optimal HPV vaccine choices.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a proportionate outcomes static cohort model to evaluate the potential impact and cost-effectiveness of HPV vaccination for 9-year-old girls over a ten-year period (2022\u20132031) in Burkina Faso. The primary outcome measure was the cost (2022 US$) per disability-adjusted life year (DALY) averted from a limited societal perspective (including all vaccine costs borne by the government and Gavi, radiation therapy costs borne by the government, and all other direct medical costs borne by patients and their families). We evaluated four vaccines (CERVARIX\u00ae, CECOLIN\u00ae, GARDASIL-4\u00ae, GARDASIL-9\u00ae), comparing each to no vaccination (and no change in existing cervical cancer screening and treatment strategies) and to each other. We combined local estimates of HPV type distribution, healthcare costs, vaccine coverage and costs with GLOBOCAN 2020 disease burden data and clinical trial efficacy data. We ran deterministic and probabilistic uncertainty analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HPV vaccination could prevent 37\u201372% of cervical cancer cases and deaths. CECOLIN\u00ae had the most favourable cost-effectiveness (cost per DALY averted\u2009&lt;\u20090.27 times the national gross domestic product [GDP] per capita). When cross-protection was included, CECOLIN\u00ae remained the most cost-effective (cost per DALY averted\u2009&lt;\u20090.20 times the national GDP per capita), but CERVARIX\u00ae provided greater health benefits (66% vs. 48% reduction in cervical cancer cases and deaths) with similar cost-effectiveness (cost per DALY averted\u2009&lt;\u20090.28 times the national GDP per capita, with CECOLIN\u00ae as the comparator). We estimated the annual cost of the vaccination programme at US$ 2.9, 4.1, 4.4 and 19.8\u00a0million for CECOLIN\u00ae, GARDASIL-4\u00ae, CERVARIX\u00ae and GARDASIL-9\u00ae, respectively. A single dose strategy reduced costs and improved cost-effectiveness by more than half.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>HPV vaccination is cost-effective in Burkina Faso from a limited societal perspective. A single dose strategy and\/or alternative Gavi-supported HPV vaccines could further improve cost-effectiveness.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-023-10283-3","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T15:02:14Z","timestamp":1701442934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study"],"prefix":"10.1186","volume":"23","author":[{"given":"Jo\u00ebl Arthur","family":"Kiendr\u00e9b\u00e9ogo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick Raissa O.","family":"Sidibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislain Bertrand","family":"Compaor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Relwend\u00e9","family":"Nacanabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orokia","family":"Sory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E","family":"Schuind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"10283_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018 Nov 1 [cited 2022 Nov 10];68(6):394\u2013424. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"10283_CR2","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May [cited 2022 Nov 10];71(3):209\u201349. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33538338\/.","DOI":"10.3322\/caac.21660"},{"key":"10283_CR3","unstructured":"International Agency for Research on Cancer (IARC) - World Health Organization. Cervix uteri - Source: Globocan 2020. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/23-Cervix-uteri-fact-sheet.pdf."},{"key":"10283_CR4","unstructured":"Global Cancer Data. : GLOBOCAN 2018 | UICC [Internet]. [cited 2021 May 17]. Available from: https:\/\/www.uicc.org\/news\/global-cancer-data-globocan-2018."},{"key":"10283_CR5","doi-asserted-by":"crossref","unstructured":"Paavonen J, Naud P, Salmer\u00f3n J, Wheeler CM, Chow SN, Apter D et al. Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet [Internet]. 2009 [cited 2022 Nov 10];374(9686):301\u201314. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19586656\/.","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"10283_CR6","doi-asserted-by":"crossref","unstructured":"Garland SM, Kjaer SK, Mu\u00f1oz N, Block SL, Brown DR, Dinubile MJ et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis [Internet]. 2016 Aug 15 [cited 2022 Nov 10];63(4):519\u201327. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27230391\/.","DOI":"10.1093\/cid\/ciw354"},{"key":"10283_CR7","doi-asserted-by":"crossref","unstructured":"Herweijer E, Sundstr\u00f6m K, Ploner A, Uhnoo I, Spar\u00e9n P, Arnheim-Dahlstr\u00f6m L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population\u2010based study. Int J Cancer [Internet]. 2016 Jun 6 [cited 2022 Dec 4];138(12):2867. Available from: http:\/\/pmc\/articles\/PMC5069657\/.","DOI":"10.1002\/ijc.30035"},{"key":"10283_CR8","unstructured":"Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev [Internet]. 2018 May 9 [cited 2022 Nov 10];5(5). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29740819\/."},{"key":"10283_CR9","unstructured":"World Health Organization (WHO). Tackling NCDs. : \u2018best buys\u2019 and other recommended interventions for the prevention and control of noncommunicable diseases [Internet]. Geneva; 2017 [cited 2022 Dec 5]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/259232."},{"key":"10283_CR10","unstructured":"World Health Organization (WHO). WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva; 2019."},{"key":"10283_CR11","unstructured":"World Health Organization (WHO). WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/www.who.int\/news\/item\/18-05-2018-who-dg-calls-for-all-countries-to-take-action-to-help-end-the-suffering-caused-by-cervical-cancer."},{"key":"10283_CR12","doi-asserted-by":"crossref","unstructured":"Akhatova A, Azizan A, Atageldiyeva K, Ashimkhanova A, Marat A, Iztleuov Y et al. Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State. Vaccines (Basel) [Internet]. 2022 Nov 11 [cited 2022 Dec 5];10(11):1912. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36423008\/.","DOI":"10.3390\/vaccines10111912"},{"key":"10283_CR13","unstructured":"Arr\u00eat\u00e9 C. N\u00b02018 \u2013 1211\/MS\/MINEFID. Manuel de proc\u00e9dures descriptives des modalit\u00e9s de gestion, de suivi et de contr\u00f4le des mesures de gratuit\u00e9 des soins au profit des femmes et des enfants de moins de cinq (05) ans vivant au Burkina Faso. 2018."},{"key":"10283_CR14","unstructured":"Minist\u00e8re de la sant\u00e9 du Burkina Faso. HPV vaccination pilot project Burkina Faso - Rapport de la mise en \u0153uvre de la d\u00e9monstration de la vaccination contre les infections \u00e0 papillomavirus (HPV) dans les districts sanitaires de Baskuy et de Solenzo. Ouagadougou; 2017."},{"key":"10283_CR15","unstructured":"Organisation mondiale de la sant\u00e9 (OMS). | Bureau r\u00e9gional pour l\u2019Afrique. Le Burkina Faso introduit le vaccin contre le HPV (papillomavirus Humain) responsable du cancer du col de l\u2019ut\u00e9rus [Internet]. 2022 [cited 2022 Dec 5]. Available from: https:\/\/www.afro.who.int\/fr\/countries\/burkina-faso\/news\/le-burkina-faso-introduit-le-vaccin-contre-le-hpv-papillomavirus-humain-responsable-du-cancer-du-col."},{"key":"10283_CR16","unstructured":"The World Bank. School enrollment, primary, female (% gross) - Burkina Faso | Data [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/data.worldbank.org\/indicator\/SE.PRM.ENRR.FE?locations=BF."},{"key":"10283_CR17","unstructured":"Human papillomavirus vaccines. WHO position paper - PubMed. Wkly Epidemiol Rec [Internet]. 2009 Apr 10 [cited 2022 Nov 10];84(15):118\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19360985\/."},{"key":"10283_CR18","unstructured":"World Health Organization = Organisation mondiale de la Sant\u00e9. Meeting of the Strategic Advisory Group of Experts on Immunization., April 2022: conclusions and recommendations \u2013 R\u00e9union du Groupe strat\u00e9gique consultatif d\u2019experts sur la vaccination, avril 2022: conclusions et recommandations [Internet]. Vol.\u00a097, Weekly Epidemiological Record = Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire. 2022 [cited 2022 Dec 23]. p.\u00a0261\u201376. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/356580."},{"key":"10283_CR19","unstructured":"United Nations - Department of Economic and Social Affairs - Population Division. World Population Prospects [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/population.un.org\/wpp\/."},{"key":"10283_CR20","unstructured":"OANDA. Currency Converter | Foreign Exchange Rates [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/www.oanda.com\/currency-converter\/en\/?from=USD&to=XOF&amount=1."},{"key":"10283_CR21","unstructured":"Ochalek J, Lomas J, Claxton K. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data. Working Papers [Internet]. 2015 [cited 2022 Dec 23]; Available from: https:\/\/ideas.repec.org\/p\/chy\/respap\/122cherp.html."},{"key":"10283_CR22","unstructured":"The World Bank. GDP per capita (current US$) - Burkina Faso [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=BF."},{"key":"10283_CR23","unstructured":"World health Organization - International Agency for Research on Cancer. Cancer Today [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/gco.iarc.fr\/today\/home."},{"key":"10283_CR24","doi-asserted-by":"crossref","unstructured":"Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health [Internet]. 2015 Nov 1 [cited 2022 Dec 5];3(11):e712\u201323. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26475018\/.","DOI":"10.1016\/S2214-109X(15)00069-8"},{"key":"10283_CR25","doi-asserted-by":"crossref","unstructured":"Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N\u2019da G et al. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int J Cancer [Internet]. 2020 Dec 1 [cited 2022 Dec 5];147(11):3037\u201348. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32449157\/.","DOI":"10.1002\/ijc.33120"},{"key":"10283_CR26","unstructured":"American Cancer Society. Survival Rates for Cervical Cancer [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/www.cancer.org\/cancer\/cervical-cancer\/detection-diagnosis-staging\/survival.html."},{"key":"10283_CR27","unstructured":"World Health Organization. Immunization, Vaccines and Biologicals. MI4A Vaccine purchase data [Internet]. [cited 2022 Dec 20]. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/vaccine-access\/mi4a\/mi4a-vaccine-purchase-data."},{"key":"10283_CR28","unstructured":"UNICEF Supply Division. EPI Logistics Forecasting Tool 2022 [spreadsheet]."},{"key":"10283_CR29","unstructured":"UNICEF Supply Division. Handling fees [Internet]. [cited 2022 Dec 23]. Available from: https:\/\/www.unicef.org\/supply\/handling-fees."},{"key":"10283_CR30","unstructured":"Minist\u00e8re de la. Sant\u00e9 Du Burkina Faso. Plan D\u2019introduction Du Vaccin anti-HPV. Ouagadougou; 2017."},{"key":"10283_CR31","volume-title":"Molecular mechanisms in Cancer","author":"TM Zohoncon","year":"2022","unstructured":"Zohoncon TM, Ouedraogo RA, Djigma FW, Traore L, Ouedraogo TWC, Ilboudo M, et al. Molecular epidemiology of high-risk human papillomavirus Infection in Burkina Faso. In: Budak M, Rajkumar R, editors. Molecular mechanisms in Cancer. London: IntechOpen; 2022."},{"key":"10283_CR32","unstructured":"HPV INFORMATION CENTRE [Internet]. [cited 2023 Jun 6]. Available from: https:\/\/hpvcentre.net\/."},{"key":"10283_CR33","unstructured":"Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG et al. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst [Internet]. 2020 [cited 2022 Dec 21];112(2):145\u201353. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31086947\/."},{"key":"10283_CR34","doi-asserted-by":"crossref","unstructured":"Apter D, Wheeler CM, Paavonen J, Castellsagu\u00e9 X, Garland SM, Skinner SR et al. Efficacy of Human Papillomavirus 16 and 18 (HPV-16\/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. Clin Vaccine Immunol [Internet]. 2015 Apr 1 [cited 2022 Dec 21];22(4):361. Available from: \/pmc\/articles\/PMC4375348\/.","DOI":"10.1128\/CVI.00591-14"},{"key":"10283_CR35","doi-asserted-by":"crossref","unstructured":"Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet [Internet]. 2007 Jun 2 [cited 2022 Dec 21];369(9576):1861\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17544766\/.","DOI":"10.1016\/S0140-6736(07)60852-6"},{"key":"10283_CR36","doi-asserted-by":"publisher","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine [Internet]. 2007 May 10 [cited 2022 Dec 21];356(19):1928\u201343. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/nejmoa061760.","DOI":"10.1056\/nejmoa061760"},{"key":"10283_CR37","doi-asserted-by":"crossref","unstructured":"Wheeler CM, Castellsagu\u00e9 X, Garland SM, Szarewski A, Paavonen J, Naud P et al. Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol [Internet]. 2012 Jan [cited 2022 Dec 21];13(1):100\u201310. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22075170\/.","DOI":"10.1016\/S1470-2045(11)70287-X"},{"key":"10283_CR38","doi-asserted-by":"crossref","unstructured":"Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Mauricio HA, Wheeler CM et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16\u201326 Years. J Infect Dis [Internet]. 2009 Apr 1 [cited 2022 Dec 21];199(7):926\u201335. Available from: https:\/\/academic.oup.com\/jid\/article\/199\/7\/926\/853088.","DOI":"10.1086\/597307"},{"key":"10283_CR39","doi-asserted-by":"crossref","unstructured":"Barnabas Rv, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL et al. Efficacy of single-dose HPV vaccination among young African women. Nejm Evidence [Internet]. 2022 Apr 26 [cited 2022 Dec 23];1(5). Available from: http:\/\/pmc\/articles\/PMC9172784\/.","DOI":"10.1056\/EVIDoa2100056"},{"key":"10283_CR40","doi-asserted-by":"publisher","unstructured":"Davis R. Teaching Project Simulation in Excel Using PERT-Beta Distributions. INFORMS Transactions on Education [Internet]. 2008 May 1 [cited 2022 Dec 30];8(3):139\u201348. Available from: https:\/\/pubsonline.informs.org\/doi\/abs\/https:\/\/doi.org\/10.1287\/ited.1080.0013.","DOI":"10.1287\/ited.1080.0013"},{"key":"10283_CR41","doi-asserted-by":"crossref","unstructured":"Bertram MY, Lauer JA, de Joncheere K, Edejer T, Hutubessy R, Kieny MP et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ [Internet]. 2016 Dec 1 [cited 2022 Dec 23];94(12):925\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27994285\/.","DOI":"10.2471\/BLT.15.164418"},{"key":"10283_CR42","doi-asserted-by":"crossref","unstructured":"Goldie SJ, O\u2019Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine [Internet]. 2008 May 15 [cited 2022 Nov 10];26(32):4080\u201393. Available from: https:\/\/europepmc.org\/article\/med\/18550229.","DOI":"10.1016\/j.vaccine.2008.04.053"},{"key":"10283_CR43","doi-asserted-by":"crossref","unstructured":"Rosettie KL, Joffe JN, Sparks GW, Aravkin A, Chen S, Compton K et al. Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis. PLoS One [Internet]. 2021 Dec 1 [cited 2022 Nov 10];16(12):e0260808. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0260808.","DOI":"10.1371\/journal.pone.0260808"},{"key":"10283_CR44","doi-asserted-by":"crossref","unstructured":"Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study. Lancet Glob Health [Internet]. 2014 Jul 1 [cited 2023 Jan 4];2(7):e406\u201314. Available from: http:\/\/www.thelancet.com\/article\/S2214109X14702372\/fulltext.","DOI":"10.1016\/S2214-109X(14)70237-2"},{"key":"10283_CR45","doi-asserted-by":"publisher","unstructured":"Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J et al. The current state of introduction of human papillomavirus vaccination into national immunization schedules in Europe: First results of the VENICE2 2010 survey. Eurosurveillance [Internet]. 2010 Nov 25 [cited 2022 Nov 10];15(47):19730. Available from: https:\/\/www.eurosurveillance.org\/content\/https:\/\/doi.org\/10.2807\/ese.15.47.19730-en.","DOI":"10.2807\/ese.15.47.19730-en"},{"key":"10283_CR46","doi-asserted-by":"publisher","first-page":"A85","DOI":"10.1016\/j.vaccine.2021.07.027","volume":"40","author":"E Vodicka","year":"2022","unstructured":"Vodicka E, Nonvignon J, Antwi-Agyei KO, Bawa J, Clark A, Pecenka C, et al. The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana. Vaccine. 2022;40:A85\u201393.","journal-title":"Vaccine"},{"key":"10283_CR47","unstructured":"World Health Organization. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer [Internet]. 2022 [cited 2023 Jan 3]. Available from: https:\/\/www.who.int\/news\/item\/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-10283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-10283-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-10283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T15:05:35Z","timestamp":1701443135000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-10283-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10283"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-10283-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with relevant guidelines and regulations, including the Declaration of Helsinki and has received an ethical approval from the Health Research Ethics Committee from Burkina Faso (deliberation N\u00b02021-07-175). All research participants (experts providing advice) gave voluntary and informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Two co-authors, ASi and IO, were actively involved in the introduction of the HPV vaccine in Burkina Faso. However, this did not influence the results of the study. Rather, it facilitated access to data to conduct the study. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1338"}}